logo

Sarepta Therapeutics (SRPT)



Trade SRPT now with
  Date
  Headline
2/5/2018 7:25:07 AM William Blair Reiterates Sarepta Therapeutics (SRPT) At Outperform
1/8/2018 2:00:29 PM Sarepta Therapeutics Expects Q4 Revenues Of $57.3 Mln And FY17 Revenues Of $154.6 Mln
12/27/2017 8:31:15 AM Sarepta Therapeutics Announces Publication Of Long-Term Pulmonary Function Of Eteplirsen-Treated Patients
12/5/2017 8:36:33 AM Sarepta Therapeutics Adds Michael Bonney To Its Board
11/9/2017 9:52:02 PM Sarepta Announces Exercise Of Initial Purchasers’ Option To Purchase Additional Convertible Senior Notes Due 2024
11/7/2017 4:18:28 PM Sarepta Therapeutics Plans Offering Of $375 Mln Of Convertible Senior Notes Due 2024
11/7/2017 8:32:06 AM Sarepta Announces FDA Clearance Of IND For PPMO Exon 51 Candidate, SRP-5051
11/6/2017 8:32:18 AM Sarepta And Nationwide Children’s Hospital Announce FDA Clearance Of IND For Micro-Dystrophin Gene Therapy Program
11/3/2017 8:32:52 AM Sarepta, Nationwide Children’s Hospital Announce FDA Clearance Of IND Application For GALGT2 Gene Therapy Program
10/31/2017 8:32:29 AM Sarepta Therapeutics Signs Exclusive Global Collaboration With Duke University For Gene Editing CRISPR/Cas9 Technology
10/25/2017 4:09:30 PM Sarepta Therapeutics Q3 Loss/share $0.78 Vs. Loss $1.18 Year Ago
9/25/2017 8:31:10 AM Sarepta Therapeutics Appoints Guriqbal Basi As Chief Scientific Officer